SCHEMBL13620388

SCHEMBL13620388

O=C(Cl)C(Cc1ccc(F)c(F)c1)c1ccccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MME P08473 1/20 0.42
PPARG P37231 1/20 0.40
GRM4 Q14833 2/20 0.39
SCD O00767 1/20 0.38
ALDH1A1 P00352 2/20 0.37
CYP2C19 P33261 1/20 0.37
PIN1 Q13526 1/20 0.37
CHRNA7 P36544 1/20 0.37
AKT1 P31749 1/20 0.36
AKT2 P31751 1/20 0.36
AKT3 Q9Y243 1/20 0.36
NPC1 O15118 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.35
CXCR3 P49682 1/20 0.35
CYP1A2 P05177 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
TP53 P04637 1/20 0.35
HAT1 O14929 1/20 0.35
EP300 Q09472 1/20 0.35
HSD17B14 Q9BPX1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1127294 0.91 MME (0.41) MMEPPARGGRM4ALDH1A1CYP2C19
SCHEMBL1127513 0.84 KMT2A (0.50) MMEGRM4ALDH1A1CHRNA7PTGDR2
SCHEMBL13662193 0.81 MME (0.39) MMEPPARGGRM4ALDH1A1CYP2C19
SCHEMBL4281403 0.79 KMT2A (0.46) MMEPPARGGRM4ALDH1A1CHRNA7
SCHEMBL13662245 0.76 PPARG (0.35) MMEPPARGGRM4SCDALDH1A1
SCHEMBL1127590 0.75 KMT2A (0.46) MMEPPARGNPC1CYP1A2
SCHEMBL1127686 0.74 PTPRA (0.41) MMEPPARGALDH1A1CYP2C19CYP1A2
SCHEMBL4281414 0.73 MME (0.38) MMEPPARGALDH1A1CHRNA7PTGDR2
SCHEMBL27142407 0.72 SMN1; SMN2 (0.46) MMEALDH1A1PTGDR2
SCHEMBL1127361 0.72 CYP1A2 (0.53) ALDH1A1CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication EIF2AK2, HAVCR2, HDGF MME 377/4885PPARG 3420/4885GRM4 4733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.